

Notice of Allowability	Application No.	Applicant(s)	
	09/992,149	BROWN ET AL.	
	Examiner N. M. Minnifield	Art Unit 1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 5/10/04 and 5/26/04.
2. The allowed claim(s) is/are 1-13 and 15; now renumbered 1-14 respectively.
3. The drawings filed on _____ are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of
 Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

N. M. Minnifield
Primary Examiner
Art Unit: 1645

ALLOWANCE


1. Applicants' amendment after final filed May 10, 2004 is acknowledged and has been entered. Claim 14 has been canceled. Claim 5 has been amended. Claims 1-13 and 15 are now pending in the present application. All rejections have been withdrawn in view of Applicants' amendments to the claims and/or the comments set forth in the after final amendment as well as the 5/26/04 telephonic interview.
2. The Brown Declaration under 37 CFR 1.132 filed May 10, 2004 is sufficient to overcome the rejection of claims 1-15 based upon 35 U.S.C. 103(a) as being unpatentable over Nash et al 1985 (J. Reprod. Immunol., 7:151-162) or Alving et al (6110492) taken with Glenn et al (5980898), Gupta et al (Vaccine, 1993, 11/13:293-306) and Edelman et al (Intern. Rev. Immunol., 1990, 7/1:51-66).
3. Claims 1-13 and 15 have been allowed and renumbered 1-14 respectively.
4. The following is an examiner's statement of reasons for allowance: the closest prior art does not disclose or teach a vaccine compositions comprising the combination of a carrier comprising a continuous phase of a hydrophobic substance, a liposome, antigen and adjuvant, wherein the antigen is encapsulated in said liposomes, and the antigen, which when not in said vaccine composition has a conformation other than its native conformation with the proviso that said antigen is other than a zona pellucida-derived antigen.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 571-272-0860. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette R.F. Smith can be reached on 571-272-0864. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).


N. M. Minnifield
Primary Examiner
Art Unit 1645

NMM

May 27, 2004